Furthermore, for the subgroup of patients with ECOG PS 0–1, median rwOS was 25.1 (95% CI: 14.9–NR), 17.6 (95% CI: 14.3–NR), and 11.3 (95% CI: 9.2–21.3) months for those who received PD-1/PD-L1 inhibitor monotherapy, PD-1/PD-L1 inhibitor combination, and PBC combination respectively (Table 4). This evidence concerns the gene CD274 and primary biliary cholangitis.